Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$31.71 - $43.0 $91,959 - $124,700
-2,900 Reduced 96.67%
100 $3,000
Q1 2022

Apr 14, 2022

SELL
$29.88 - $37.04 $38,545 - $47,781
-1,290 Reduced 30.07%
3,000 $111,000
Q4 2021

Jan 18, 2022

BUY
$25.61 - $35.1 $89,378 - $122,499
3,490 Added 436.25%
4,290 $130,000
Q2 2021

Jul 19, 2021

BUY
$34.54 - $47.25 $24,178 - $33,075
700 Added 700.0%
800 $31,000
Q4 2018

Feb 05, 2019

SELL
$43.37 - $59.54 $21,685 - $29,770
-500 Reduced 83.33%
100 $5,000
Q3 2018

Nov 07, 2018

BUY
$42.88 - $53.7 $11,577 - $14,499
270 Added 81.82%
600 $30,000
Q2 2018

Aug 10, 2018

BUY
$40.53 - $50.7 $9,321 - $11,661
230 Added 230.0%
330 $13,000
Q1 2018

May 11, 2018

SELL
$44.08 - $55.05 $436,259 - $544,829
-9,897 Reduced 99.0%
100 $4,000
Q4 2017

Jan 17, 2018

SELL
$50.3 - $64.39 $329,163 - $421,368
-6,544 Reduced 39.56%
9,997 $502,000
Q3 2017

Oct 17, 2017

BUY
$45.56 - $59.57 $753,607 - $985,347
16,541
16,541 $838,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.64B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.